Healio (8/17, Gramigna) reports, “Austedo [deutetrabenazine] treatment appeared to improve involuntary movements and quality of life [QoL] among older adults with tardive dyskinesia,” researchers concluded in “a post hoc analysis of a long-term open-label extension study” that enrolled “a total of 337 participants.” The study revealed that “a total of 67% of younger and 76% of older participants, as well as 64% of younger and 63% of older participants, achieved treatment success,” and “both groups generally well tolerated deutetrabenazine.” The findings were published online Aug. 15 ahead of print in the American Journal of Geriatric Psychiatry.
Related Links:
— “Austedo improves quality of life in older adults with tardive dyskinesia “Joe Gramigna, Healio, August 17, 2021